Skip to main content

Advertisement

Table 3 A570 values of different treatments when adding drug and virus simultaneously (n = 6)

From: Assessment of the hepatocyte protective effects of gypenoside and its phosphorylated derivative against DHAV-1 infection on duck embryonic hepatocytes

GP Concentration (μg.mL− 1) A 570 Hepatocyte protection rate rate(%) pGP Concentration (μg.mL− 1) A 570 Hepatocyte protection rate rate(%)
100 0.515 ± 0.004a 108.74 25 0.509 ± 0.003a 99.26
50 0.425 ± 0.008b 59.56 12.5 0.487 ± 0.005a 82.96
25 0.374 ± 0.008c 31.69 6.25 0.421 ± 0.007b 34.07
12.5 0.353 ± 0.008d 20.22 3.125 0.422 ± 0.010b 34.81
6.25 0.336 ± 0.008de 10.93 1.563 0.401 ± 0.007bc 19.26
3.125 0.322 ± 0.007e 3.28 0.781 0.396 ± 0.007bc 15.56
0(VC) 0.316 ± 0.006e   0(VC) 0.375 ± 0.005c  
0(CC) 0.499 ± 0.005a   0(CC) 0.510 ± 0.005a  
  1. a-eData in same column without same superscript (a–e) differ significantly(P < 0.05)
  2. GP Gypenoside, pGP phosphorylated gypenoside, VC virus control, CC cell control